Because of the predominant role estrogens play in the development of breast cancer and the limited effectiveness of tamoxifen therapy, more selective therapeutics targeting estrogen signaling have been developed: selective estrogen receptor modulators (SERMs), selective estrogen receptor downregulators (SERDs), and a third generation of drugs that inhibit the aromatase required for estrogen biosyntheses. The authors examine clinical and translational research results from studies of these endocrine therapies and ...
Read More
Because of the predominant role estrogens play in the development of breast cancer and the limited effectiveness of tamoxifen therapy, more selective therapeutics targeting estrogen signaling have been developed: selective estrogen receptor modulators (SERMs), selective estrogen receptor downregulators (SERDs), and a third generation of drugs that inhibit the aromatase required for estrogen biosyntheses. The authors examine clinical and translational research results from studies of these endocrine therapies and chemotherapies in pre- and postmenopausal women with early and advanced breast cancer. Advances in Endocrine Therapy of Breast Cancer provides guidance on promising new therapeutics and treatment combinations based on compelling clinical evidence.
Read Less
Add this copy of Advances in Endocrine Therapy of Breast Cancer to cart. $85.00, like new condition, Sold by Rob the Book Man rated 4.0 out of 5 stars, ships from Vancouver, WA, UNITED STATES, published 2004 by Marcel Dekker.
Add this copy of Advances Ednocrine Theraphy Breast to cart. $102.36, new condition, Sold by Books International rated 3.0 out of 5 stars, ships from Toronto, ON, CANADA, published 2004 by CRC Press Inc.
